Tuesday, 28 March 2017


Pharma major, Suven Life Sciences, has added another product patent from New Zealand, to its list of 25 other patents from New Zealand. The patent valid through 2033, is concerning its molecule to be used for treating neuro-degenerative diseases.

These patents, achieved through sophisticated internal discovery and research, are intellectual property rights exclusive to Suven Life Sciences. While the company might out license the patents at the clinical development phases like phase I or phase II.

 The new developments by the pharma major aid the treatment of cognitive impairments, like the Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Huntington's disease, major depressive disorders, Parkinsons and Schizophrenia. As on March 28, 2017, stock of Suven Life Sciences is trading at Rs 169.75 on BSE, up by 1.37%.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 

0 comments: